☰

Manuela Corti - Publications

Affiliations: 
University of Florida & VA BRRC, Gainesville, FL, United States 
Area:
motor control, neurorehabilitation, neural plasticity
Tree Info Grants Similar researchers PubMed Report error

18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. Brain Sciences. 10. PMID 32098339 DOI: 10.3390/Brainsci10020119  0.329
2020 Salabarria SM, Nair J, Clement N, Smith BK, Raben N, Fuller DD, Byrne BJ, Corti M. Advancements in AAV-mediated Gene Therapy for Pompe Disease. Journal of Neuromuscular Diseases. 7: 15-31. PMID 31796685 DOI: 10.3233/Jnd-190426  0.332
2019 Corti M, Casamento Moran A, Delmas S, Bracksieck S, Bowman J, Meyer B, Norman S, Subramony S, Christou EA. Temporal but not spatial dysmetria relates to disease severity in FA. Journal of Neurophysiology. PMID 31693434 DOI: 10.1152/Jn.00165.2019  0.302
2019 Byrne BJ, Fuller DD, Smith BK, Clement N, Coleman K, Cleaver B, Vaught L, Falk DJ, McCall A, Corti M. Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy. Annals of Translational Medicine. 7: 290. PMID 31392202 DOI: 10.21037/Atm.2019.05.56  0.351
2016 Smith BK, Martin AD, Lawson LA, Vernot V, Marcus J, Islam S, Shafi N, Corti M, Collins SW, Byrne BJ. Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Experimental Neurology. PMID 27453480 DOI: 10.1016/J.Expneurol.2016.07.013  0.308
2016 Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ. Targeted approaches to induce immune tolerance for Pompe disease therapy. Molecular Therapy. Methods & Clinical Development. 3: 15053. PMID 26858964 DOI: 10.1038/Mtm.2015.53  0.323
2016 Corti M, Cleaver B, Clement N, Conlon T, Faris K, Wang G, Benson J, Tarantal A, Fuller D, Herzog R, Byrne BJ. 472. Evaluation of Re-Administration of a Recombinant Adeno-Associated Vector Expressing Acid-Alpha-Glucosidase (rAAV9-DES-hGAA) in Pompe Disease: Preclinical to Clinical Planning Molecular Therapy. 24: S186-S187. DOI: 10.1016/S1525-0016(16)33281-6  0.348
2015 Smith BK, Corti M, Martin AD, Fuller DD, Byrne BJ. Altered Activation of the Diaphragm in Late-Onset Pompe Disease. Respiratory Physiology & Neurobiology. PMID 26612101 DOI: 10.1016/J.Resp.2015.11.013  0.338
2015 Colon-Perez LM, Triplett W, Bohsali A, Corti M, Nguyen PT, Patten C, Mareci TH, Price CC. A majority rule approach for region-of-interest-guided streamline fiber tractography. Brain Imaging and Behavior. PMID 26572144 DOI: 10.1007/S11682-015-9474-5  0.439
2015 Corti M, Cleaver B, Clément N, Conlon TJ, Faris KJ, Wang G, Benson J, Tarantal AF, Fuller D, Herzog RW, Byrne BJ. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning. Human Gene Therapy. Clinical Development. 26: 185-93. PMID 26390092 DOI: 10.1089/Humc.2015.068  0.346
2015 Corti M, Smith BK, Falk DJ, Lawson LA, Fuller DD, Subramony SH, Byrne BJ, Christou EA. Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction. Muscle & Nerve. 51: 877-83. PMID 25186912 DOI: 10.1002/Mus.24444  0.325
2015 Love-Leonor T, Corti M, Boye S, Donate A, Santostefano K, Cloutier D, Clemente N, Pacak C, Byrne B. 191. Frataxin: A Putative Biomarker for Minimal Effective Dosage of AAV Gene Therapy Molecular Therapy. 23: S76. DOI: 10.1016/S1525-0016(16)33796-0  0.301
2014 Corti M, Elder M, Falk D, Lawson L, Smith B, Nayak S, Conlon T, Clément N, Erger K, Lavassani E, Green M, Doerfler P, Herzog R, Byrne B. B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study. Molecular Therapy. Methods & Clinical Development. 1. PMID 25541616 DOI: 10.1038/Mtm.2014.33  0.318
2013 Mah CS, Soustek MS, Todd AG, McCall A, Smith BK, Corti M, Falk DJ, Byrne BJ. Adeno-associated virus-mediated gene therapy for metabolic myopathy. Human Gene Therapy. 24: 928-36. PMID 24164240 DOI: 10.1089/Hum.2013.2514  0.302
2013 Fuller DD, ElMallah MK, Smith BK, Corti M, Lawson LA, Falk DJ, Byrne BJ. The respiratory neuromuscular system in Pompe disease. Respiratory Physiology & Neurobiology. 189: 241-9. PMID 23797185 DOI: 10.1016/J.Resp.2013.06.007  0.33
2013 Corti M, Baligand C, Falk L, Walter GA, Byrne BJ. P.17.4 Magnetic Resonance Imaging (MRI) to evaluate the effect of enzyme replacement therapy in Late Onset Pompe Disease (LOPD) Neuromuscular Disorders. 23: 827. DOI: 10.1016/J.Nmd.2013.06.654  0.311
2012 Corti M, McGuirk TE, Wu SS, Patten C. Differential effects of power training versus functional task practice on compensation and restoration of arm function after stroke. Neurorehabilitation and Neural Repair. 26: 842-54. PMID 22357633 DOI: 10.1177/1545968311433426  0.44
2012 Corti M, Patten C, Triggs W. Repetitive transcranial magnetic stimulation of motor cortex after stroke: a focused review. American Journal of Physical Medicine & Rehabilitation / Association of Academic Physiatrists. 91: 254-70. PMID 22042336 DOI: 10.1097/Phm.0B013E318228Bf0C  0.452
Show low-probability matches.